ArticleStem cell research & therapy2022
Adipose-derived stem cells ameliorate atopic dermatitis by suppressing the IL-17 expression of Th17 cells in an ovalbumin-induced mouse model.
Article in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Thermogelling Hydrogel for Sustained Topical Delivery of Quercetin for the Treatment of Atopic Dermatitis.AAPS PharmSciTech · 2026Article
- Targeting macrophage polarization: mechanisms and potential of mesenchymal stromal/stem cells therapy in acne treatment- a narrative review.Frontiers in immunology · 2026Review
- Therapeutic roles of natural and engineered mesenchymal stem cells and extracellular vesicles in atopic dermatitis.Regenerative therapy · 2025Review
- Conditioned medium from stem cells of human exfoliated deciduous teeth ameliorates mouse ovalbumin-specific allergic dermatitis.Stem cell research & therapy · 2025Article
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- Exosomes and Exosome-Mimetics for Atopic Dermatitis Therapy.Tissue engineering and regenerative medicine · 2025Review
- New insights into mesenchymal stem cells in inflammatory subtypes of asthma.Frontiers in immunology · 2025Review
- Adipose-derived stem cells in immune-related skin disease: a review of current research and underlying mechanisms.Stem cell research & therapy · 2024Review
- Therapeutic Potential and Mechanisms of Mesenchymal Stem Cell and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atopic Dermatitis.Journal of inflammation research · 2024Review
- Cell-free fat extract regulates oxidative stress and alleviates Th2-mediated inflammation in atopic dermatitis.Frontiers in bioengineering and biotechnology · 2024Article
- Attenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine.Cell reports. Medicine · 2023Article
- Impact of atorvastatin and mesenchymal stem cells combined with ivermectin on murine trichinellosis.Parasitology research · 2023Article
- Review
- Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis.Frontiers in immunology · 2023Review
- Mechanotransduction through adhesion molecules: Emerging roles in regulating the stem cell niche.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stem cells (MSCs) have therapeutic potential for atopic dermatitis (AD) owing to their immunoregulatory effects. However, the underlying mechanisms associated with the therapeutic efficacy of MSCs on AD are diverse and related to both cell type and delivery method.
objectivesThis study investigated the therapeutic effect and mechanisms of adipose-derived stem cells (ADSCs) on AD using an ovalbumin (OVA)-induced AD mouse model.
methodsAD mice were subcutaneously injected with mouse ADSCs, cortisone, or PBS, and the therapeutic effects were determined by gross and histological examinations and serum IgE levels. Additionally, qPCR, RNA-sequencing analyses of skin samples and co-culture of ADSCs and Th17 cells were conducted to explore the underlying therapeutic mechanisms.
resultsADSCs treatment attenuated the AD pathology, decreased the serum IgE levels, and decreased mast cells infiltration in the skin of the model mice. Moreover, tissue levels of IL-4R and Th17-relevant products (IL-17A, CCL20, and MMP12) were suppressed in the ADSC- and cortisone-treated groups. Genomics and bioinformatics analyses demonstrated significant enrichment of inflammation-related pathways in the downregulated genes of the ADSC- and cortisone-treated groups, specifically the IL-17 signaling pathway. Co-culture experiments revealed that ADSCs significantly suppressed the proliferation of Th17 cells and the expression of proinflammatory cytokines (IL-17A and RORγT). Furthermore, expression levels of PD-L1, TGF-β, and PGE2 were significantly upregulated in co-cultured ADSCs relative to those in monocultured ADSCs.
conclusionADSCs ameliorate OVA-induced AD in mice mainly by downregulating IL-17 secretion of Th17 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.